Hidradenitis Suppurativa – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hidradenitis Suppurativa – Pipeline Review, H1 2018’, provides an overview of the Hidradenitis Suppurativa pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa

– The report reviews pipeline therapeutics for Hidradenitis Suppurativa by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hidradenitis Suppurativa therapeutics and enlists all their major and minor projects

– The report assesses Hidradenitis Suppurativa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Celgene Corp

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Immunwork Inc

InflaRx NV

Innovation Pharmaceuticals Inc

Novartis AG

UCB SA

XBiotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hidradenitis Suppurativa - Overview

Hidradenitis Suppurativa - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hidradenitis Suppurativa - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hidradenitis Suppurativa - Companies Involved in Therapeutics Development

AbbVie Inc

Celgene Corp

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Immunwork Inc

InflaRx NV

Innovation Pharmaceuticals Inc

Novartis AG

UCB SA

XBiotech Inc

Hidradenitis Suppurativa - Drug Profiles

adalimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimekizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJM-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Xilonix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hidradenitis Suppurativa - Dormant Projects

Hidradenitis Suppurativa - Discontinued Products

Hidradenitis Suppurativa - Product Development Milestones

Featured News & Press Releases

Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology

Oct 31, 2017: Innovation Pharma Provides Update on Brilacidin

Oct 03, 2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board

Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa

Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Jun 12, 2017: AbbVie's Humira accepted for use in NHS Scotland

Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application

Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa

Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa

Nov 14, 2016: AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease

Sep 26, 2016: AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress

Aug 03, 2016: Clinical trial results support adalimumab treatment for painful skin condition

May 09, 2016: Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hidradenitis Suppurativa – Pipeline by AbbVie Inc, H1 2018

Hidradenitis Suppurativa – Pipeline by Celgene Corp, H1 2018

Hidradenitis Suppurativa – Pipeline by Coherus BioSciences Inc, H1 2018

Hidradenitis Suppurativa – Pipeline by Fresenius SE & Co KGaA, H1 2018

Hidradenitis Suppurativa – Pipeline by Immunwork Inc, H1 2018

Hidradenitis Suppurativa – Pipeline by InflaRx NV, H1 2018

Hidradenitis Suppurativa – Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Hidradenitis Suppurativa – Pipeline by Novartis AG, H1 2018

Hidradenitis Suppurativa – Pipeline by UCB SA, H1 2018

Hidradenitis Suppurativa – Pipeline by XBiotech Inc, H1 2018

Hidradenitis Suppurativa – Dormant Projects, H1 2018

Hidradenitis Suppurativa – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports